Viewing nowCombinationDaparon Duo Extended Release Tablet 5/500 mg
Metformin Hydrochloride 500mg · Dapagliflozin Bis L-proline 7.8mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 202202497 · Approved 2022.06.15 · Insurance code 643508560
Improvement of glycemic control in adults with type 2 diabetes
This medication is used in conjunction with dietary and exercise therapy to help control blood glucose levels in adult patients with type 2 diabetes who are suitable for combination therapy with dapagliflozin and metformin. Special caution is needed for patients with type 2 diabetes who have cardiovascular disease or cardiovascular risk factors and whose blood glucose is insufficiently controlled. In such patients, it is important to refer to professional information regarding the impact of dapagliflozin on cardiovascular events. In summary, this drug is used to improve blood glucose control in type 2 diabetes patients while considering cardiovascular health.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients treated with metformin, the recommended dose of dapagliflozin is 10mg once daily; the dose of this medicine should provide the same dose of metformin the patient was taking, or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because any change may cause changes in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This drug is a combination agent used for the treatment of type 2 diabetes. When taking this medication, there is a very rare but serious metabolic complication known as lactic acidosis that may occur, so caution is advised. The risk of lactic acidosis may increase in cases of impaired kidney function, severe infection, dehydration, or heart problems. Additionally, this medication may cause hypoglycemia when taken with insulin or sulfonylureas, so careful monitoring of blood glucose changes is necessary. It should not be administered to patients with moderate to severe renal impairment or those with dehydration, severe infections, acute myocardial infarction, septicemia, etc. This medication is also prohibited for use in patients undergoing surgery, those with severe infections, heart failure patients, and women who are pregnant or breastfeeding. In elderly patients or those with reduced kidney function, regular assessment of fluid volume status and kidney function is necessary, and dose adjustment is needed to reduce the risk of hypotension or kidney damage. This drug can increase urination, potentially causing reduced fluid volume and hypotension; therefore, particular caution is necessary for elderly patients or those taking antihypertensive medications. While taking this medication, there may be an increased risk of genital and urinary tract infections; if infection symptoms appear, consult healthcare professionals immediately. This medication may cause vitamin B12 deficiency; therefore, monitoring through blood tests is necessary for long-term use. Excessive alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid alcohol while taking this medication. During pregnancy or breastfeeding, this medication should not be used, and it should be discontinued immediately if pregnancy is confirmed. The risk of hypoglycemia may increase when this medication is used in combination with other diabetes treatments, thus dosage adjustments are essential. In the case of overdose, immediate medical attention is required, and dialysis may be beneficial if needed. Caution is also necessary while driving or operating machinery, as dizziness may occur during treatment. Keep the medication out of reach of children and store it in its original container to prevent degradation of quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture, at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain its effectiveness over time.
Orange biconvex rectangular extended release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 500mg · Dapagliflozin Bis L-proline 7.8mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationDapagliflozin Bis L-proline 15.63mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
CombinationDapagliflozin Bis L-proline 15.63mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
CombinationDapagliflozin Bis L-proline 15.63mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Bis L-proline 15.63mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Bis L-proline 15.63mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Cheil Pharmaceutical Co., Ltd.
CombinationDapagliflozin Bis L-proline 15.63mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
CombinationDapagliflozin Bis L-proline 15.63mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.